Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma Thymoma and thymic carcinoma are rare neoplasms of the mediastinum, arising from the epithelial cells of the thymus. While surgical resection is the treatment of choice in early stages, platin-based chemotherapy is mainly used in patients with advanced or metastatic disease; however, the prognosis is poor. Here we present the case of a 54 year old female patient suffering from a CD117-negative thymic carcinoma with widespread metastases. After several courses of different kinds of chemotherapy, finally these approaches failed to be effective. Thus we initiated a treatment with sorafenib, an inhibitor of several receptor tyrosine kinases. The treatment was tolerated very well, and within a few weeks the general condition of the patient improved significantly. A CT-scan, performed 3 months after therapy with sorafenib started, showed a 50 % reduction of tumor size, and this effect lasted for 15 months. When the carcinoma relapsed again, we administered another course of chemotherapy and, because of lacking success, we even tried to use sunitinib. However, the patient died in a septic shock, based on progressive disease. In summary, we present a patient with metastastic thymic carcinoma, in which sorafenib led to a tumor-control for 18 months. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma

Neuhaus, Thomas; Luyken, Joachim
Targeted Oncology , Volume 7 (4) – Oct 23, 2012
Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/long-lasting-efficacy-of-sorafenib-in-a-heavily-pretreated-patient-3ZWBxQJ5mZ

References (42)

Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag France
Subject
Medicine & Public Health; Oncology; Biomedicine general
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-012-0235-8
pmid
23090205
Publisher site
See Article on Publisher Site

Abstract

Thymoma and thymic carcinoma are rare neoplasms of the mediastinum, arising from the epithelial cells of the thymus. While surgical resection is the treatment of choice in early stages, platin-based chemotherapy is mainly used in patients with advanced or metastatic disease; however, the prognosis is poor. Here we present the case of a 54 year old female patient suffering from a CD117-negative thymic carcinoma with widespread metastases. After several courses of different kinds of chemotherapy, finally these approaches failed to be effective. Thus we initiated a treatment with sorafenib, an inhibitor of several receptor tyrosine kinases. The treatment was tolerated very well, and within a few weeks the general condition of the patient improved significantly. A CT-scan, performed 3 months after therapy with sorafenib started, showed a 50 % reduction of tumor size, and this effect lasted for 15 months. When the carcinoma relapsed again, we administered another course of chemotherapy and, because of lacking success, we even tried to use sunitinib. However, the patient died in a septic shock, based on progressive disease. In summary, we present a patient with metastastic thymic carcinoma, in which sorafenib led to a tumor-control for 18 months.

Journal

Targeted Oncology – Springer Journals

Published: Oct 23, 2012

There are no references for this article.